Andrew Weinberg earned his M.S. and Ph.D. in Biochemistry at Washington State University in 1987.  Dr. Weinberg moved to Portland, Oregon in 1990 to work at the VA Medical Center on an autoimmune model for multiple sclerosis (EAE) with Arthur Vandenbark, Ph.D. and Halina Offner, Ph.D.  During the course of the autoimmune work Dr. Weinberg discovered that the TNF-receptor, OX40, was expressed on autoAg-specific T cells at the site of autoimmune inflammation and was in part responsible for their pathogenic properties.  Dr. Weinberg moved to the Providence Cancer Center in 1995 as an independent scientist to focus on tumor immunology.  There he discovered that OX40 agonists were potent stimulators of tumor immunity in cancer-bearing hosts.  In collaboration with Brendan Curti, M.D. and Walter Urba, M.D. at the Providence Cancer Center a human OX40 agonist was tested in a phase I clinical trial.